Loading company financials…
NASDAQ NMS - GLOBAL MARKET · Biotechnology · CIK 0000872589
$805.67
-0.22% · delayed ~15 min
Last price from Oct 21, 2026
$84.27B market value
From REGENERON PHARMACEUTICALS, INC.'s FY2025 10-K, filed Feb 4, 2026 · read the filing
REGENERON PHARMACEUTICALS develops and makes medicines. It took in $14.34B last year, which makes it a large company. Of every dollar it sells, about 31 cents is left as profit.
The financial picture is led by profitability and debt, with growth worth watching.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
Strong finances across the board.
From REGENERON PHARMACEUTICALS, INC.'s FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Dividends paid
$0.00 → $370.3M
Operating margin
28.1% → 24.9%
Cash
$2.49B → $3.12B
Capital spending
$755.9M → $898.4M
Measured against FY2024, from the 10-K filed Feb 4, 2026
Changed: turned positive
$0.00 to $370.3MCritical
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
How the latest move compares (quote delayed ~15 min), and what was published around it
REGN fell 0.22% on the latest quote. The average Health Care company tracked here moved +1.62%, and the S&P 500 −1.04%. That is 1.8 points below its sector and 0.8 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 6% a year for the next 10 years. Over the last 10 years it grew by about 20% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 31 cents of every dollar of sales as profit, earning $4.50B last year.
Barely. Sales were roughly flat, up 1.0%.
No — it holds more cash than debt, with $1.13B left over after paying off every borrowing. For every $1 it owes, it owns $4.36 in assets.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 8 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 7% of the cash its operations generated.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $4.50B and generated $4.98B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 4, 2026Filing for FY2025 | FY202410-K · Feb 4, 2026Filing for FY2024 | FY202310-K · Feb 4, 2026Filing for FY2023 | FY202210-K · Feb 6, 2023Filing for FY2022 | FY202110-K · Feb 7, 2022Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | +1.0% |
| Selling, general and administrative | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | −8.6% |
| Operating income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | −10.3% |
| Operating marginOperating income ÷ revenueWhat is this? | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | −3.2 pts |
| Interest expense | $43.8M | $55.2M | $73.0M | $59.4M | $57.3M | −20.7% |
| Income before tax | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | +9.4% |
| Net income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | +2.1% |
| Net marginNet income ÷ revenueWhat is this? | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | +0.3 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | +5.3% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| REGNREGENERON PHARMACEUTICALS, INC. · this page | 8.7/10 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Exercised stock options — 17,000 shares at $381.92 ($6.5M)
Holds 64,833 shares after this filing.
Had shares withheld to cover taxes — 12,853 shares at $754.58 ($9.7M)
Holds 51,980 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Signed a material agreement · Published results · Reported another event
Read the filingHad a director or senior officer leave or join
Read the filingWrite down why you are following REGENERON PHARMACEUTICALS, INC., what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
The 30 subsidiaries named in its 10-K, incorporated across 15 places. A filer lists the significant ones and may leave the rest out, so this is the floor rather than the full count.
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from REGN's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 4, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 8 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 8.7 | 6/8 | 10-K, filed Feb 4, 2026 |
| FY2024 | 8.7 | 6/8 | 10-K, filed Feb 5, 2025 |
| FY2023 | 8.7 | 6/8 | 10-K, filed Feb 5, 2024 |
| FY2022 | 7.3 | 6/8 | 10-K, filed Feb 6, 2023 |
| FY2021 | 10.0 | 6/8 | 10-K, filed Feb 7, 2022 |
| FY2020 | 10.0 | 5/8 | 10-K, filed Feb 8, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 8 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's. One could not be evaluated and is excluded from the total rather than counted as a failure.
7.72
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: −3.1 pts
28.1% to 24.9%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +25.3%
$2.49B to $3.12BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Changed: +18.9%
$755.9M to $898.4MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Deteriorated: -10.3%
$3.99B to $3.58BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +11.3%
$3.66B to $4.08BNotable
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +5.3%
$40.90 to $43.07Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: -3.1%
107.9M to 104.6MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 30, 2026 — read it.
Improved: +16.7%
$3.68B to $4.29BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +19.8%
$1.08B to $1.29BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: −7.6 pts
37.9% to 30.2%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +23.0%
$2.00B to $2.46BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Deteriorated: -6.8%
$1.39B to $1.30BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: -2.2%
105.1M to 102.8MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 30, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +101.2%
$642.9M to $1.29BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +78.3%
$727.2M to $1.30BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +12.3 pts
17.8% to 30.1%Critical
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +10.1 pts
20.2% to 30.2%Critical
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +80.4%
$6.99 to $12.62Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +19.0%
$3.61B to $4.29BSignificant
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: -17.1%
$2.96B to $2.46BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: -1.2%
104.0M to 102.8MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 4% and 8%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Opinions from 37 analysts covering this company, as of . Their views, not this site's.
Of 37 analysts publishing on this company, 8 say strong buy, 18 say buy and 11 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.1% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 17.3x — investors pay $17.3 for each $1 of trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 6/8 |
| 1.0% |
| 31.4% |
| 18.71x |
| 0.30x |
| ABBVAbbVie Inc. | 7.0/10 | 8/9 | 8.6% | 6.9% | 119.13x | -41.97x |
|---|
| AMGNAMGEN INC | 8.0/10 | 8/9 | 10.0% | 21.0% | 31.25x | 9.46x |
|---|
| GILDGILEAD SCIENCES, INC. | 9.0/10 | 8/9 | 2.4% | 28.9% | 22.92x | 1.60x |
|---|
| VRTXVERTEX PHARMACEUTICALS INC / MA | 8.7/10 | 6/8 | 8.9% | 32.9% | 34.38x | 0.37x |
|---|
| MRNAModerna, Inc. | 6.0/10 | 3/9 | -39.9% | -145.2% | — | 0.43x |
|---|
| Median of peers | 8.0/10 | — | 8.6% | 21.0% | 32.82x | 0.43x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 6 shares at $753.76 ($4.5K)
Holds 51,974 shares after this filing.
Sold on the open market — 35 shares at $755.91 ($26.5K)
Holds 51,939 shares after this filing.
Sold on the open market — 16 shares at $757.68 ($12.1K)
Holds 51,923 shares after this filing.
Sold on the open market — 24 shares at $758.16 ($18.2K)
Holds 51,899 shares after this filing.
Sold on the open market — 14 shares at $759.96 ($10.6K)
Holds 51,885 shares after this filing.
Sold on the open market — 74 shares at $760.65 ($56.3K)
Holds 51,811 shares after this filing.
Sold on the open market — 27 shares at $761.36 ($20.6K)
Holds 51,784 shares after this filing.
Sold on the open market — 55 shares at $762.57 ($41.9K)
Holds 51,729 shares after this filing.
Sold on the open market — 25 shares at $763.76 ($19.1K)
Holds 51,704 shares after this filing.
Sold on the open market — 219 shares at $764.40 ($167.4K)
Holds 51,485 shares after this filing.
Sold on the open market — 271 shares at $765.39 ($207.4K)
Holds 51,214 shares after this filing.
Sold on the open market — 279 shares at $766.47 ($213.8K)
Holds 50,935 shares after this filing.
Sold on the open market — 192 shares at $767.39 ($147.3K)
Holds 50,743 shares after this filing.
Sold on the open market — 105 shares at $768.33 ($80.7K)
Holds 50,638 shares after this filing.
Sold on the open market — 127 shares at $769.30 ($97.7K)
Holds 50,511 shares after this filing.
Sold on the open market — 12 shares at $770.20 ($9.2K)
Holds 50,499 shares after this filing.
Sold on the open market — 283 shares at $771.56 ($218.4K)
Holds 50,216 shares after this filing.
Sold on the open market — 211 shares at $772.56 ($163.0K)
Holds 50,005 shares after this filing.
Sold on the open market — 224 shares at $773.40 ($173.2K)
Holds 49,781 shares after this filing.
Sold on the open market — 121 shares at $774.48 ($93.7K)
Holds 49,660 shares after this filing.
Sold on the open market — 376 shares at $775.46 ($291.6K)
Holds 49,284 shares after this filing.
Sold on the open market — 66 shares at $776.31 ($51.2K)
Holds 49,218 shares after this filing.
Sold on the open market — 38 shares at $777.76 ($29.6K)
Holds 49,180 shares after this filing.
Sold on the open market — 454 shares at $778.64 ($353.5K)
Holds 48,726 shares after this filing.
Sold on the open market — 380 shares at $779.59 ($296.2K)
Holds 48,346 shares after this filing.
Sold on the open market — 463 shares at $780.63 ($361.4K)
Holds 47,883 shares after this filing.
Sold on the open market — 50 shares at $781.47 ($39.1K)
Holds 47,833 shares after this filing.
Exercised stock options — 400 shares at $719.37 ($287.7K)
Holds 1,003 shares after this filing.
Sold on the open market — 400 shares at $850.00 ($340.0K)
Holds 603 shares after this filing.
Sold on the open market — 1,215 shares at $850.00 ($1.0M)
Holds 13,134 shares after this filing.
Sold on the open market — 1,131 shares at $857.39 ($969.7K)
Holds 12,003 shares after this filing.
Exercised stock options — 12,282 shares at $381.92 ($4.7M)
Holds 45,392 shares after this filing.
Had shares withheld to cover taxes — 9,019 shares at $830.15 ($7.5M)
Holds 36,373 shares after this filing.
Exercised stock options — 6,283 shares at $381.92 ($2.4M)
Holds 24,583 shares after this filing.
Had shares withheld to cover taxes — 4,599 shares at $813.47 ($3.7M)
Holds 19,984 shares after this filing.
Exercised stock options — 800 shares at $376.69 ($301.4K)
Holds 2,503 shares after this filing.
Sold on the open market — 800 shares at $800.00 ($640.0K)
Holds 1,703 shares after this filing.
Exercised stock options — 400 shares at $719.37 ($287.7K)
Holds 1,003 shares after this filing.
Sold on the open market — 400 shares at $800.00 ($320.0K)
Holds 603 shares after this filing.
Sold on the open market — 200 shares at $650.15 ($130.0K)
Holds 17,303 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 4,147 shares ($3.2M) on or after .
Shares originally obtained via Exercise of Stock Options.
Filed notice to sell 1,131 shares ($969.3K) on or after .
Shares originally obtained via RSA Vesting.
Filed notice to sell 400 shares ($340.0K) on or after .
Shares originally obtained via Exercise of stock option.
Filed notice to sell 1,215 shares ($1.0M) on or after .
Shares originally obtained via RSA Vesting.
Filed notice to sell 400 shares ($320.0K) on or after .
Shares originally obtained via Exercise of stock option.
Filed notice to sell 800 shares ($640.0K) on or after .
Shares originally obtained via Exercise of stock options.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q2 FY2026
Revenue +16.7% · Profit margin −7.6 pts · Operating income +19.8% — against Q2 FY2025
Published results
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +19.0% · Operating margin −1.7 pts · Profit margin −6.5 pts — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingPublished results
Read the filingAnnual report for FY2025
Operating margin −3.1 pts · Dividends paid turned positive · Cash +25.3% — against FY2024
Read the filingPublished results
Read the filingPublished results · Made a Regulation FD disclosure
Read the filingQuarterly report for Q3 FY2025
Operating margin −4.3 pts · Cash +24.6% · Operating income -12.9% — against Q3 FY2024
Read the filingPublished results
Read the filingPublished results
Read the filingQuarterly report for Q2 FY2025
Profit margin −2.5 pts · Shares in issue -2.8% — against Q2 FY2024
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2025
Operating margin −4.4 pts · Free cash flow -40.8% · Dividends paid turned positive — against Q1 FY2024
Read the filingSource: Exhibit 21 of the 10-K filed 2026-02-04. These are legal entities, not brands or acquisitions — a company that bought a business may hold it inside an entity named here, or inside one small enough that the rule does not require naming it at all.
Coverage from the last 30 days
Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?
Yahoo ·
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Yahoo ·
TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $980
Benzinga ·
Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
SeekingAlpha ·
Why Should You Think About Vertex Differently Now?
Yahoo ·
Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free
SeekingAlpha ·
EyePoint halves workforce and ends Phase III trial early after endpoint miss
Yahoo ·
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results
Yahoo ·
How Much Upside Is Left In Regeneron Stock?
Yahoo ·
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Yahoo ·
Piper Sandler Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $865
Benzinga ·
Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?
Yahoo ·
Primary sources and further research